Defibrotide is indicated for patients who develop severe sinusoidal obstructive syndrome following allogeneic hematopoietic cell transplantation (allo-HCT). Preclinical data suggested that defibrotide carries a prophylactic effect against acute graft-versus-host disease (aGVHD).
Objective
The purpose of this study was to investigate the effect of defibrotide on the incidence and severity of aGVHD.
Methods
This single-center retrospective study included all consecutive transplanted patients between January 2014 and December 2018. A propensity score based on 10 predefined confounders was used to estimate the effect of defibrotide on aGVHD via inverse probability of treatment weighting (IPTW).
Results
Of the 482 included patients, 64 received defibrotide (defibrotide group) and 418 did not (control group). Regarding main patient characteristics and transplantation modalities, the two groups were comparable, except for a predominance of men in the defibrotide group. The median age was 55 years (interquartile range [IQR]: 40-62). Patients received allo-HCT from HLA-matched related donor (28.6%), HLA-matched unrelated donor (50.8%), haplo-identical donor (13.4%), or mismatched unrelated donor (7.0%). Stem cell source was either bone marrow (49.6%) or peripheral blood (50.4%). After using IPTW, exposure to defibrotide was not significantly associated with occurrence of aGVHD (HR = 0.97; 95% CI 0.62-1.52; P = .9) or occurrence of severe aGVHD (HR = 1.89, 95% CI: 0.98-3.66; P = .058).
Conclusion and Relevance
Defibrotide does not seem to have a protective effect on aGVHD in patients undergoing allo-HCT. Based on what has been reported to date and on these results, defibrotide should not be considered for the prevention of aGVHD outside clinical trials.
RichardsonPGCarrerasEIacobelliMNejadnikB. The use of defibrotide in blood and marrow transplantation. Blood Adv. 2018;2(12):1495–1509. doi:10.1182/bloodadvances.2017008375.
2.
CorbaciogluSCesaroSFaraciM, et al. Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial. Lancet. 2012;379(9823):1301–1309. doi:10.1016/S0140-6736(11)61938-7.
3.
TekgündüzEKayaAHBozdağSC, et al. Does defibrotide prophylaxis decrease the risk of acute graft versus host disease following allogeneic hematopoietic cell transplantation?Transfus Apher Sci. 2016;54(1):30–34. doi:10.1016/j.transci.2016.01.009.
4.
HillGRFerraraJL. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood. 2000;95(9):2754–2759.
5.
HillGRKoyamaM. Cytokines and costimulation in acute graft-versus-host disease. Blood. 2020;136(4):418–428. doi:10.1182/blood.2019000952.
6.
SociéGBlazarBR. Acute graft-versus-host disease: from the bench to the bedside. Blood. 2009;114(20):4327–4336. doi:10.1182/blood-2009-06-204669.
PrzepiorkaDWeisdorfDMartinP, et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15(6):825–828.
9.
CarrerasEDiaz-RicartM. The role of the endothelium in the short-term complications of hematopoietic SCT. Bone Marrow Transplant. 2011;46(12):1495–1502. doi:10.1038/bmt.2011.65.
10.
CoppellJARichardsonPGSoifferR, et al. Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. Biol Blood Marrow Transplant. 2010;16(2):157–168. doi:10.1016/j.bbmt.2009.08.024.
11.
BonifaziFBarbatoFRavaioliF, et al. Diagnosis and treatment of VOD/SOS after allogeneic hematopoietic stem cell transplantation. Front Immunol. 2020;11:489. doi:10.3389/fimmu.2020.00489.
12.
CarrerasE. Vascular endothelial syndromes after HCT: 2020 update. Bone Marrow Transplant. 2020;55(10):1885–1887. doi:10.1038/s41409-020-0852-2.
13.
TichelliAGratwohlA. Vascular endothelium as “novel” target of graft-versus-host disease. Best Pract Res Clin Haematol. 2008;21(2):139–148. doi:10.1016/j.beha.2008.02.002.
14.
NomuraSIshiiKFujitaSNakayaASatakeAItoT. Associations between acute GVHD-related biomarkers and endothelial cell activation after allogeneic hematopoietic stem cell transplantation. Transpl Immunol. 2017;43–44:27-32. doi:10.1016/j.trim.2017.06.004.
15.
AzizMTKakadiyaPPKushSMWeigelKLoweDK. Defibrotide: an oligonucleotide for sinusoidal obstruction syndrome. Ann Pharmacother. 2018;52(2):166–174. doi:10.1177/1060028017732586.
Martinez-SanchezJHamelmannHPalomoM, et al. Acute graft-vs.-host disease-associated endothelial activation in vitro is prevented by defibrotide. Front Immunol. 2019;10:2339. doi:10.3389/fimmu.2019.02339
18.
García-BernalDPalomoMMartínezCM, et al. Defibrotide inhibits donor leucocyte-endothelial interactions and protects against acute graft-versus-host disease. J Cell Mol Med. 2020;24(14):8031–8044. doi:10.1111/jcmm.15434.
MohtyMMalardFAbecassisM, et al. Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant. 2016;51(7):906–912. doi:10.1038/bmt.2016.130.
21.
JonesRJLeeKSBeschornerWE, et al. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation. 1987;44(6):778–783. doi:10.1097/00007890-198712000-00011.
22.
Yakoub-AghaI. [Fourth annual series of workshops of the SFGM-TC to harmonize practices in allogeneic stem cell transplantation]. Pathol Biol (Paris). 2014;62(4):179. doi:10.1016/j.patbio.2014.05.001.
23.
ChaoN. How I treat sinusoidal obstruction syndrome. Blood. 2014;123(26):4023–4026. doi:10.1182/blood-2014-03-551630.
24.
SpyridonidisALabopinMSavaniBN, et al. Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients. Bone Marrow Transplant. 2020;55(6):1114–1125. doi:10.1038/s41409-020-0803-y.
25.
DignanFLWynnRFHadzicN, et al. BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation. Br J Haematol. 2013;163(4):444–457. doi:10.1111/bjh.12558.
FlowersMEDInamotoYCarpenterPA, et al. Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood. 2011;117(11):3214–3219. doi:10.1182/blood-2010-08-302109.
28.
SorrorMLStorerBStorbRF. Validation of the hematopoietic cell transplantation-specific comorbidity index (HCT-CI) in single and multiple institutions: limitations and inferences. Biol Blood Marrow Transplant. 2009;15(6):757–758. doi:10.1016/j.bbmt.2009.02.007.
29.
KumarSDeleveLDKamathPSTefferiA. Hepatic veno-occlusive disease (sinusoidal obstruction syndrome) after hematopoietic stem cell transplantation. Mayo Clin Proc. 2003;78(5):589–598. doi:10.4065/78.5.589.
30.
JagasiaMAroraMFlowersMED, et al. Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood. 2012;119(1):296–307. doi:10.1182/blood-2011-06-364265.
31.
SteelandtJBocquetFCordonnierALDe CourtivronCFusierIPaubelP. Defibrotide in severe sinusoidal obstruction syndrome: medicine and economic issues. Biol Blood Marrow Transplant. 2017;23(2):347–356. doi:10.1016/j.bbmt.2016.11.020.
32.
CorbaciogluSJabbourEJMohtyM. Risk factors for development of and progression of hepatic veno-occlusive disease/sinusoidal obstruction syndrome. Biol Blood Marrow Transplant. 2019;25(7):1271–1280. doi:10.1016/j.bbmt.2019.02.018.
33.
Jazz Pharmaceuticals. A Phase 2, prospective, randomized, open-label study on the efficacy of defibrotide added to standard of care immunoprophylaxis for the prevention of acute graft-versus-host-disease in adult and pediatric patients after allogeneic hematopoietic stem cell transplant. clinicaltrials.gov. Published 2021. Accessed October 14, 2021. https://clinicaltrials.gov/ct2/show/results/NCT03339297.
